

9th ANNUAL ACUTE

LEUKEMIA MEETING

23rd-26th SEPTEMBER 2020

VIRTUAL MEETING

COORDINATORS

Dr. Miguel Ángel Sanz
Hospital Universitario y Politécnico La Fe, Valencia, España

Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España

MD Anderson
~~Cancer Center~~
Madrid • España

#MadridLeukemia

www.mdanderson.es/cursouleucemia



WEDNESDAY, 23rd SEPTEMBER 2020

16:00 - 18:00 MEET THE EXPERT: CML Cases

Chairs: Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA
Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain

THURSDAY, 24th SEPTEMBER 2020

16:00 - 16:10 Welcome

16:10 - 17:25 SESSION 1 - Diagnostic

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Joaquín Sánchez, Hospital Reina Sofía, Córdoba, Spain

16:10 - 16:30 Impact of coexisting mutations and mechanisms of resistance to new agents

Dr. M^a José Calasanz, CIMA LAB Diagnostics UNAV, Pamplona, Spain

16:30 - 16:50 Major altered signaling pathways in AML

Dr. Joaquín Sánchez, Hospital Reina Sofía, Córdoba, Spain

16:50 - 17:10 MRD assessment and follow up

Dr. Konstanze Döhner, Universitätsklinikum Ulm, Germany

17:10 - 17:25 Discussion

17:25 - 17:40 Break

17:40 - 19:15 SESSION 2 - Myeloid malignancies MDS & MF

Chairs: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
TBC

19:40 - 18:00 CMML management

Dr. Breno Gusmão, Hospital Beneficência Portuguesa, São Paulo, Brasil

18:00 - 18:20 Management of lower risk MDS

Dr. María Díez Campelo, Hospital Clínico Universitario de Salamanca, Spain

18:20 - 18:40 Prognostic and management of myelofibrosis patients that fail to conventional treatment

Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain

18:40 - 19:00 Oral therapies in MDS

Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA

19:00 - 19:15 Discussion

FRIDAY, 25th SEPTEMBER 2020

13:30 - 14:05 SESSION 3 - AML -2

13:30 - 13:50 Hope and future

Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

13:50 - 14:05 Discussion

14:05 - 15:40 SESSION 4 - ALL

Chairs: Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

14:05 - 14:25 First-line therapy of Ph-positive ALL: current status and perspectives

Dr. Sabina Chiaretti, Sapienza University, Rome, Italy

14:25 - 14:45 Adult LAL: real-life treatment results

Dr. Josep M^a Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain

14:45 - 15:05 Optimizing 1st line therapy based on MRD in ALL

Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA

15:05 - 15:25 Case based discussion: Introducing new agents in day to day practice

Dr. Claudio Cerchione, AOU Federico II, Naples, Italy

15:25 - 15:40 Discussion

15:40 - 15:55 Break

15:55 - 17:10 SESSION 5 - AML -1

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

15:55 - 16:15 AML management ELN 2017 update

Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany

16:15 - 16:35 Moving toward targeted approaches in AML

Dr. Richard Stone, Dana-Farber Cancer Institute, Boston, USA

16:35 - 16:55 Update in Bcl2 inhibitors

Dr. Daniel Pollyea, University of Colorado School of Medicine, USA

16:55 - 17:10 Discussion

17:10 - 17:25 Break

17:25 - 19:05 SESSION 6 - Immunotherapy

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

17:25 - 17:45 Immunotherapy in ALL

Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA

17:45 - 18:05 Harnessing the immune system for threatening AML

Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

18:05 - 18:25 CAR T: organization and start-up of a unit

Dr. Manuel Guerreiro, Hospital Universitario y Politécnico La Fe, Valencia, Spain

18:25 - 18:45 CAR-T cell therapy in adult patients with ALL

Dr. Nicolas Boissel, Hôpital Saint-Louis, Paris, France

18:45 - 19:05 Immunotherapy approaches in MDS

Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA

19:05 - 19:20 Discussion

SATURDAY, 26th SEPTEMBER 2020

09:30 - 11:05 SESSION 7 - AML-3

Chairs: Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

09:30 - 09:50 First line FLT3 AML

Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

09:50 - 10:10 Study of relapsed LAM

Dr. Eva Barragán, Hospital Universitario y Politécnico La Fe, Valencia, Spain

10:10 - 10:30 Salvage therapy FLT-3

Dr. Josefina Serrano, Hospital Universitario Reina Sofía, Córdoba, España

10:30 - 10:50 The challenge of starting maintenance after transplant

Dr. Giovanni Martinelli, University of Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy

10:50 - 11:05 Discussion

11:05 - 11:20 Break

11:20 - 13:55 SESSION 8 - AML-4. Session high risk

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

11:20 - 11:40 Accurate diagnosis

Dr. Jordi Esteve, Hospital Clinic, Barcelona, Spain

11:40 - 12:00 Goals not achieved in the Fit patient with AML. Decreasing mortality

Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain

12:00 - 12:20 Current status of the transplant indication

Dr. Jaime Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

12:20 - 12:40 New formulations

Dr. Raquel Sánchez, MD Anderson Cancer Center Madrid, Spain

12:40 - 13:00 New ways to deliver induction chemotherapy in AML

Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain

13:00 - 13:20 Houston experience

Dr. Guillermo Montalbán Bravo, MD Anderson Cancer Center, Houston, USA

13:20 - 13:40 UK experience

TBC

13:40 - 13:55 Discussion

13:55 - 14:10 Break

14:10 - 15:40 SESSION 9 - COVID 19

Chairs: Dr. Josep M^a Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

14:10 - 14:30 COVID 19 Session: presentation

Dr. Josep M^a Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain

14:30 - 15:40 Discussion

Dr. Jaime Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany
Dr. Breno Gusmão, Hospital Beneficência Portuguesa, São Paulo, Brasil
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

15:40 - 15:50 Closing

SPONSORS

PLATINUM



GOLD



SILVER



COLLABORATOR



ORGANIZED BY



CREDITS

Continuing Education Credits requested to the Spanish National Health System.
With the collaboration of the Educational Committee of MD Anderson Cancer Center Madrid.

TECHNICAL SECRETARIAT

